TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04023916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab-R-CHOP
Description: Drug:Sintilimab:~Sintilimab:200 mg IV on Day 1 Cycles 2-8, during induction treatment, followed by 200 mg IV on Day 1 of Cycles 9-14.~Drug: Rituximab Rituximab:Participants with previously untreated DLBCL will receive rituximab at a dose of 375 mg/m\^2 IV on Day 1 of Cycle 1-8, during induction treatment.~Drug: Cyclophosphamide Cyclophosphamide will be administered at a dose of 750 mg/m\^2 IV on Day 2 of Cycle 1-6, during induction treatment.~Drug: Doxorubicin Hydrochloride Liposome Injection Doxorubicin Hydrochloride Liposome Injection will be administered at a dose of 35 mg/m\^2 IV on Day 2-3 of Cycle 1-6, during induction treatment.~Drug: Vincristine Vincristine will be administered at a dose of 1.4 mg/m\^2 (maximum 2 mg) IV on Day 2 of Cycle 1-6, during induction treatment.~Drug: Prednisone Prednisone will be administered at a dose of 40 mg/m\^2 orally on Days 1-5 of Cycle 1-6, during induction treatment. Prednisolone may be given if prednisone is unavailable.
Study: NCT02536430

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Tromethamine
Description: One group received a buccal infiltration of Ketorolac Tromethamine
Study: NCT00360737

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum Antitoxin Heptavalent (A B C D E F G) - (EQUINE)
Description: Biological/Vaccine NP-018 (heptavalent equine-derived botulinum antitoxin) is prepared from pooled plasma obtained from horses that have been immunized against one of seven botulinum antitoxins (A-G). .

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum Antitoxin Heptavalent (A B C D E F G) - (EQUINE)
Description: Biological/Vaccine NP-018 (heptavalent equine-derived botulinum antitoxin) is prepared from pooled plasma obtained from horses that have been immunized against one of seven botulinum antitoxins (A-G). .
Study: NCT02507440

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Prior to initiation of anesthesia viscous lidocaine or placebo will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Prior to initiation of anesthesia viscous lidocaine or placebo will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: All patients will receive intravenous propofol as anesthesia for EGD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: All patients will receive intravenous propofol as anesthesia for EGD
Study: NCT00956787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-67 (20S)-7-t-Butyldimethylsilyl-10-hydroxycamptothecin)
Description: Patients will receive AR-67 at an initial dose of 7.5 mg/m2 IV over 1 hour daily for 5 days. In patients with stable disease, treatment may continue for up to a total of 12 courses of therapy; about 1 to 2 years.
Study: NCT01376310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212
Description: up to 2 mg/day
Study: NCT02536430

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: buccal infiltration of Normal Saline.
Study: NCT03575819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOR46
Description: FOR46 is an intravenously (IV) administered antibody-drug conjugate (ADC) directed against CD46
Study: NCT01376310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212
Description: up to 2 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel + GSK1120212
Description: dose as defined in the dose escalation protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib + GSK1120212
Description: dose as defined in the dose escalation protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed + GSK1120212
Description: dose as defined in the dose escalation protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin + GSK1120212
Description: dose as defined in the dose escalation protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel + GSK1120212
Description: dose as defined in the dose escalation protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine + GSK1120212
Description: dose as defined in the dose escalation protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus + GSK1120212
Description: dose as defined in the dose escalation protocol
Study: NCT01849016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04815395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Administration of oxytocin (24IU) orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Administration of oxytocin (24IU) intranasally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of placebo orally
Study: NCT06082297

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chattanooga Physio, DJO, neuromuscular electrical stimulation
Description: Neuromuscular electrical stimulation (NMES) was applied with a device called Chattanooga Physio (DJO), testing 10 different combinations of parameter-settings. The parameter-settings that were varied and combined were frequency (1Hz and 36Hz) and plateau times (0.5s, 1.5s, 3s, 5s, 7s). The NMES was applied to the calf of the participants via transversally placed textile electrodes (3x3 cm) integrated in a sock starting with very low current amplitude followed by gradual small increases in current amplitude until induction of ankle plantar flexion, at which time-point the outcomes where measured.
Study: NCT01885416

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: consumption of test meal based on dairy products

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: consumption of high fat test meal without dairy products

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: consumption of high fat test meal with dairy products
Study: NCT04227938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALPN-101
Description: A single dose of ALPN-101 will be administered via intravenous infusion.
Study: NCT02396082

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MIND-S Intervention
Description: MIND at Home is a home-based, care coordination that focuses on persons with dementia living at home and their family caregivers. Its goal is to help persons age in place safely while increasing quality of life. Delivered over 18 months, MIND systematically assesses and addresses unmet care needs of persons with dementia and their caregivers which are known to be linked to poor health and quality of life outcomes, and that put people at risk for long term care placement. The needs addressed in the MIND program cover a wide range of care domains, ranging from home and medication safety, to cognitive and behavior symptoms management, meaningful activities and legal considerations. The care team made up of a memory care coordinator, nurse, and physician. Patients and families receive care coordination assistance, resource referrals, dementia care education and behavior management skills training, emotional support and problem-solving, and home safety education

Intervention type: OTHER
Group type: OTHER
Intervention: Augmented Usual Care
Description: Augmented usual care consists of an initial full in-home needs assessment for dementia-related needs and a written report that identifies unmet needs and provides recommendations for care sent to the participant and the primary care physician. Augmented usual care participants also receive an Aging and Caregiver Resource Guide that includes program and contact information for several local and national aging service organizations (e.g., Alzheimer's Association, Administration on Aging, Centers for Medicare and Medicaid). This condition likely exceeds the usual level of intervention in primary care settings
Study: NCT03082235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6742
Description: gelatin capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6742
Description: gelatin capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6742
Description: gelatin capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6742
Description: gelatin capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6742
Description: gelatin capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6742
Description: gelatin capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6742
Description: gelatin capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: gelatin capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: gelatin capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: gelatin capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: gelatin capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: gelatin capsules
Study: NCT02221219

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indomethacin
Description: indomethacin at standard dose for prevention of intraventricular hemorrhage in preterm infants
Study: NCT03082235

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: gelatin capsules
Study: NCT02221219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: indomethacin at standard dose for prevention of intraventricular hemorrhage in preterm infants

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: delay in umbilical cord clamp at birth
Description: provision of a \~45 second delay of umbilical cord clamping at birth in preterm infants (recorded in delivery note)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: delay in umbilical cord clamp at birth
Description: provision of a \~45 second delay of umbilical cord clamping at birth in preterm infants (recorded in delivery note)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo infusion
Description: saline infusion to match input of indomethacin treatment group (and serve as drug-dosing 'blinding' for bedside staff)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo infusion
Description: saline infusion to match input of indomethacin treatment group (and serve as drug-dosing 'blinding' for bedside staff)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: immediate cord clamp at birth
Description: no delay in umbilical cord clamp; \<10sec (recorded in delivery note)

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: immediate cord clamp at birth
Description: no delay in umbilical cord clamp; \<10sec (recorded in delivery note)
Study: NCT03007836

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-activity natural killer
Description: Each treatment: 8\~10 billion cells in all, transfuion in 3 times, i.v.
Study: NCT00326924

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Transfusion
Description: PRBC blood transfusions.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Transfusion
Description: PRBC blood transfusions.
Study: NCT00774436

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: focal cryotherapy
Description: Those men meeting the re-staging biopsy criteria will subsequently be treated with focal cryotherapy. Clinical follow-up visits will be scheduled at 6 + 2 weeks, 3 + 1 months and 6 + 1 months after focal cryotherapy, at which time, a digital rectal examination and PSA test will be performed. Standard quality-of-life questionnaires, are completed by all patients treated by the Urology Service (whether on not they are treated on an IRB protocol).
Study: NCT04009642

Intervention type: OTHER
Intervention: Surely observational based on disease state
Description: Metabolism in T2DM vs non diabetic

Intervention type: OTHER
Intervention: Surely observational based on disease state
Description: Metabolism in T2DM vs non diabetic
Study: NCT01418118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: 0.2mcg/kg/min maximum infusion; to increase mean arterial pressure by 30mmHg
Study: NCT01360827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMD 1201081 + 5-FU + Cisplatin + Cetuximab
Description: 3-6 subjects per cohort will receive EMD 1201081 as a weekly subcutaneous injection on Days 1, 8, and 15 in 3-week cycles at dose levels of 0.16, 0.32, and 0.48mg/kg, respectively until progression of disease, unacceptable toxicity, or subject refusal to continue in the trial. EMD 1201081 will always be given after (within 1 hour) completion of the cetuximab infusion and before the start of chemotherapy.
Study: NCT01418118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Maximum infusion of 0.2mcg/kg/min, to increase mean arterial pressure by 30mmHg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dobutamine
Description: Maximum infusion rate of 8mcg/kg/min to increase mean arterial pressure by 30mmHg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dopexamine
Description: Maximum infusion rate of 5mcg/kg/min to increase mean arterial pressure by 30mmHg
Study: NCT03954015

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Contrast Enhanced imaging
Description: Contrast Enhanced Ultrasound (CEUS) with US Microvessel Imaging, Contrast Enhanced Dual Energy Mammography (CEDM) and Contrast Enhanced Breast MR (CEMR): Comparison of Three Methods for Early Detection of Breast Cancer.

Intervention type: DRUG
Group type: OTHER
Intervention: Lumason
Description: FDA approved and used routinely for ultrasound exams of the heart and liver as well as the urinary tract in children. It contains microbubbles that are small enough to pass through the blood stream.
Study: NCT03973684

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tongue scraper group
Description: Tongue scrapping will be performed by the same operator in all patients. Posterior -anterior movements will be performed with the scrapper over the lingual dorsum. in order to promote the mechanical removal of tongue coating
Study: NCT03870048

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: A tDCS device (Soterix) will deliver a small direct current through two sponge surface electrodes (5cm × 5cm, soaked with 15 mM NaCL). The positive electrode will be placed over the motor cortex representation of the more affected leg, and a second electrode will be placed on the forehead above the contralateral orbit.
Study: NCT03973684

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tongue scraper group
Description: Tongue scrapping will be performed by the same operator in all patients. Posterior -anterior movements will be performed with the scrapper over the lingual dorsum. in order to promote the mechanical removal of tongue coating
Study: NCT01413984

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Helping Women Recover/Beyond Trauma
Description: Four treatment rounds will be conducted, and a goal of 20 women (10 from each group) will be recruited to participate in each round. A new treatment group will start every four months. Sessions are approximately 2 hours each, 3-4 times per week over four months in a group format. This treatment program will focus on the integrated treatment of trauma and substance abuse in women. Versions of the curriculum exist both for community and corrections populations. In this intervention the corrections version will be used.
Study: NCT04476992

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitric Oxide-Sessions
Description: Nitric Oxide will be delivered at 200 ppm in 2 daily sessions (morning, evening; 9-12 hours apart) for 14 days. Each session will last 30 minutes, for a total of 60 minutes/day for each patient. A tank of NO gas will be connected to the inspiratory limb of the circuit, and the flow will be adjusted to deliver a target concentration of 200 ppm NO. Commercially available tanks will be used to provide the gas. The desired mixture of air, oxygen (O2), and NO will be titrated with the respective flowmeter to reach a concentration of 200 ppm at the inspiratory limb with the desired Fraction of inspired oxygen (FiO2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide-Continuous and Sessions
Description: Nitric Oxide will be delivered at 200 ppm in 2 daily sessions (morning, evening; 9-12 hours apart) for 14 days. Each session will last 30 minutes, for a total of 60 minutes/day for each patient. A tank of NO gas will be connected to the inspiratory limb of the circuit, and the flow will be adjusted to deliver a target concentration of 200 ppm NO. Commercially available tanks will be used to provide the gas. The desired mixture of air, oxygen (O2), and NO will be titrated with the respective flowmeter to reach a concentration of 200 ppm at the inspiratory limb with the desired Fraction of inspired oxygen (FiO2).~The subjects assigned to the group NO High Concentration + Continuous Low Concentration will receive in adjunction a continuous dose of NO at 20 ppm.
Study: NCT04597255

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Holographic optical coherence tomography
Description: Descriptive wavefront analysis with holographic optical coherence tomography
Study: NCT01209546

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: In placebo patients were assessed and were not subjected to any respiratory physical therapy technique.
Study: NCT00315705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofarabine
Description: Clofarabine 20-40 mg/m²/day 2 hour intravenous (IV) infusion daily for 5 days of a 28 day cycle as the first of the three IV interventions administered. Maximum of 8 cycles given in both the phase 1 and phase 2 study periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 75-100 mg/m²/day 2 hour intravenous (IV) infusion daily for 5 days of a 28 day cycle following clofarabine therapy. Maximum of 8 cycles given in both the phase 1 and phase 2 study periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 340-440 mg/m²/day as 30-60 minute intravenous (IV) infusion daily for 5 days of a 28 day cycle following the other two interventions. Maximum of 8 cycles given in both the phase 1 and phase 2 study periods.
Study: NCT02520778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navitoclax
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Given PO
Study: NCT02628535

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MGD009
Description: B7-H3 x CD3 DART protein
Study: NCT00892047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venlafaxine XR plus aripiprazole
Description: Dosage varies. Subject remains on antidepressant throughout the 36 week study. Will be randomized to aripiprazole or placebo for up to 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venlafaxine plus placebo
Description: Dosage varies. Subject remains on antidepressant throughout the 36 week study. Will be randomized to aripiprazole or placebo for up to 24 weeks.
Study: NCT03844932

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ST-0529
Description: ST-0529 utilizes SmPill® technology to encapsulate the otherwise insoluble cyclosporine in a presolubilized, lipid-based formulation.
Study: NCT02446002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lofexidine + Naltrexone
Description: Lofexidine HCl (two 0.2 mg tablets) will be administered as a single oral dose (0.4 mg) on Day 1 and on Day 11.Commercially available naltrexone HCL tablets will be administered as a single oral 25 mg dose on Day 4 and as a single oral 50 mg dose on Days 5 through 13. On Day 11 administration of both naltrexone and lofexidine will occur. Dose administration times for each drug are to be standardized for all treatment days. The scheduling of the naltrexone dose is to be standardized so that the naltrexone dose is administered 2 hours after the lofexidine dose on Day 11 when both drugs are administered.
Study: NCT02157909

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotrafilcon B sphere modified design contact lenses
Study: NCT03844932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST-0529
Description: ST-0529 utilizes SmPill® technology to encapsulate the otherwise insoluble cyclosporine in a presolubilized, lipid-based formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST-0529
Description: ST-0529 utilizes SmPill® technology to encapsulate the otherwise insoluble cyclosporine in a presolubilized, lipid-based formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST-0529
Description: ST-0529 utilizes SmPill® technology to encapsulate the otherwise insoluble cyclosporine in a presolubilized, lipid-based formulation.
Study: NCT01783431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly ICLC
Description: Poly-ICLC is considered an investigational drug and has not been approved by the Food and Drug Administration (FDA) for treatment of your disease. It is currently being tested in clinical trials for brain tumors, lymphoma, human immunodeficiency virus (HIV) and prostate cancer. It is thought that Poly-ICLC, when used with dendritic cells as a vaccine therapy, may work to help the immune system fight disease.
Study: NCT01360827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMD 1201081 + 5-FU + Cisplatin + Cetuximab
Description: Part 2 seeks to enroll 12 subjects at the MTD of EMD 1201081 in combination with 5-FU/cisplatin + cetuximab; furthermore, an additional 3 to 6 subjects for a total of 9 subjects will be accrued at the 0.16 mg/kg low dose level in Part 2a once the Part 1 0.16 mg/kg dose cohort has been accrued and it is deemed safe to proceed to the 0.32 mg/kg dose cohort. EMD 1201081 will always be given after (within 1 hour) completion of the cetuximab infusion and before the start of chemotherapy.
Study: NCT02157909

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lotrafilcon B sphere contact lenses
Study: NCT01783431

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: leukapheresis
Description: Leukapheresis is a process in which white blood cells are collected from the body. These cells will be given together with Poly-ICLC therapy when subjects begin study treatment.
Study: NCT03267017

Intervention type: OTHER
Intervention: posture changes
Description: Following induction of general anesthesia and initiation of positive pressure ventilation, patients will be tilted 15 degrees head up for 5 minutes with positive end expiratory pressure of 8 cm H2O, and then 15 degrees head down for 5 minutes with positive end expiratory pressure of 3 cm H2O
Study: NCT01380665

Intervention type: DEVICE
Group type: OTHER
Intervention: Prevena Incisional Management System
Description: All evaluable patients will utilize the Prevena Incisional Management System